City page
Riga biotech and pharma directory
Riga is Latvia's biotech and pharma capital, hosting the bulk of the country's diagnostic, pharmaceutical, and research operators. The cluster centers on the historic Latvian pharma industry — Grindeks (originator drugs in cardiology and oncology) — and a layer of clinical lab networks (E. Gulbis Laboratory), regulatory CROs (Inpharmatis), molecular diagnostics (Cytognos), and recombinant biotech (Asla Biotech). Olainfarm operates manufacturing nearby in Olaine. The ecosystem benefits from Latvian Institute of Organic Synthesis and University of Latvia's biotech programs.
Where does this city read strongest?
Research (2), Manufacturing (2), and Diagnostics (2). Most visible records: Biosan, E. Gulbis Laboratory, and Inpharmatis.
Which standards and public evidence are already visible?
GMP (3), ISO-13485 (1), and FDA-Inspected (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Riga.
By category
Riga by category
Jump into a category page filtered to this country only.
Full list
Riga biotech and pharma directory
11 city records currently match the active filter.
Current review cycle
Biosan
RigaLatviaTools
Latvian manufacturer of patented laboratory instruments (thermo-shakers, Reverse-Spin bioreactors, vortexes, homogenisers) for life-science research, with ISO 9001 and ISO 13485 quality systems and distribution in more than a hundred countries.
- Lead
- Svetlana BankovskaCo-Founder and Managing Director
- Scale
- Industrial laboratory-equipment manufacturing
Current review cycle
E. Gulbis Laboratory
RigaLatviaDiagnostics
Latvia's largest private clinical diagnostics network, running ISO 15189-accredited hematology, biochemistry, microbiology, molecular, and hormone panels across more than fifty service centres from a Riga hub.
- Lead
- Didzis GavarsMember of the Board and Executive Director
- Scale
- National clinical diagnostic service delivery
Current review cycle
Inpharmatis
RigaLatviaCRO
Riga-based pharmaceutical and biotech consultancy covering regulatory affairs, pharmacovigilance, GMP and GDP compliance, and eCTD publishing across the EU and CIS, with a proprietary Prudenta literature-monitoring stack.
- Lead
- Polina DombureFounder and Chief Executive Officer
- Scale
- Regulatory consulting service delivery across EU and CIS
Current review cycle
GenEra
RigaLatviaDiagnostics
Riga molecular-genetics laboratory delivering medical DNA testing, NIPT, kinship testing, next-generation sequencing, and specialist genetic diagnostics from Latvia.
- Lead
- Dr. biol. Ilze Radoviča-SpalviņaChairman of the Board
- Scale
- Clinical genetics and molecular-diagnostics platform
Current review cycle
BIOR
RigaLatviaResearch
Riga national laboratory and research institute combining analytical testing, medical laboratory services, reference-laboratory functions, and public-science infrastructure across Latvia.
- Lead
- Dr Olga ValcinaDirector
- Scale
- National research and reference-laboratory network
Current review cycle
Kalceks
RigaLatviaManufacturing
Riga pharmaceutical manufacturer developing, producing, registering, and distributing sterile hospital medicines and other finished dosage forms for international markets.
- Lead
- Egils KopstalsChairman of the Board
- Scale
- International finished-dosage manufacturing
Current review cycle
State Agency of Medicines Latvia
RigaLatviaRegulatory anchor
Riga medicines-control authority supervising authorisations, inspections, vigilance, and pharmaceutical market controls in Latvia.
- Lead
- Indra DreikaDirector
- Scale
- National medicines regulator
Current review cycle
Silvanols
RigaLatviaManufacturing
Riga phytopharma manufacturer combining herbal formulation expertise, GMP-backed production, and regional natural-products manufacturing capacity.
- Lead
- Liene PurinaMember of the Board
- Scale
- Regional Supply
Current review cycle
Institute of Organic Synthesis
RigaLatviaResearch
Riga medicinal-chemistry and drug-discovery institute combining synthetic chemistry, pharmacology, process research, and translational infrastructure inside Latvia's strongest chemistry campus.
- Lead
- Dace KārkleDirector
- Scale
- Discovery / Pilot
Current review cycle
AS Grindeks
RigaLatviaCDMO
Riga pharmaceutical manufacturing campus running API synthesis, finished-dose production, and quality-control workflows from Grindeks' long-standing Krustpils Street base.
- Lead
- Jānis RomanovskisChairman of the Board and CEO
- Scale
- Commercial / Industrial
Current review cycle
Latvia Pharma Cluster Hub
RigaLatviaCluster
Riga-based coordination hub for the Life Science Cluster of Latvia, linking pharmaceutical companies, industrial policy programs, and cross-sector business development.
- Lead
- Zanda JurjaneExecutive Director
- Scale
- National scale
FAQ
Frequently asked questions
- How many biotech companies are in Riga?
- Riga concentrates the majority of the directory's Latvian profiles — most of Latvia's biotech, pharma, and diagnostics companies are based in or around the capital. Exact count appears in the page header above and updates with each directory refresh.
- What is the biggest biotech company in Riga?
- Grindeks is the largest originator pharma company headquartered in Riga, with a strong cardiology and oncology pipeline. The Latvian Institute of Organic Synthesis (associated with Grindeks heritage) drives Riga's historical pharma chemistry strength. E. Gulbis Laboratory is the largest clinical diagnostic laboratory network. Olainfarm (Olaine, just outside Riga) is the largest generic drug manufacturer.
- What sectors are strongest in Riga biotech?
- Riga is strongest in pharmaceutical manufacturing (Grindeks, Olainfarm), clinical laboratory diagnostics (E. Gulbis Laboratory), regulatory CRO services (Inpharmatis), molecular diagnostics (Cytognos), and recombinant protein/biologics (Asla Biotech). The cluster combines historic pharma chemistry depth with growing diagnostic and biotech operators.
Related briefs
Briefs that mention Riga
Baltic CRO & Clinical Trial Landscape 2026: Lithuania, Latvia, Estonia
A practical map of the Baltic clinical research organisation landscape — Biomapas, Cureline Baltic, Inpharmatis, Asper Biogene, BioCC — and why Lithuania, Latvia, and Estonia are a credible nearshore option for EU-regulated clinical trials in 2026.
Open briefBaltic Biotech Landscape 2026: Lithuania, Latvia, Estonia
A practical map of the Baltic biotech and pharma landscape in 2026 — 74 operators across Lithuania, Latvia, and Estonia, organised by city, category, and what each actually does in the European supply chain.
Open briefEuropean Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
Where to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.